TCT 49: Coronary Perforation Incidence and Temporal Trends in Chronic Total Occlusion Percutaneous Coronary Intervention (COPIT CTO)
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; Boston Scientific Corporation; AstraZenca
- Equity/Stock(s)/Options - Shockwave